Congress moves to cap drug prices at international levels, bypassing pharma lobbying
H.R. 3493 — Global Fairness in Drug Pricing Act · Filed by Ro Khanna (D-CA) · 7 cosponsors · Introduced May 19, 2025 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill directs the Secretary of Health and Human Services to create rules that cap U.S. drug prices at levels comparable to those paid in other wealthy countries (a 'most-favored-nation' pricing model), allows individuals to import cheaper prescription drugs from developed nations, and instructs federal enforcement agencies to pursue antitrust cases against pharmaceutical companies for anticompetitive practices. The goal is to reduce what Americans pay for prescription drugs by benchmarking them to international prices.
Why we flagged it
The bill's core mechanism is price regulation and enforcement against pharmaceutical manufacturers to reduce consumer costs. It is fundamentally a consumer-protection and price-control measure, not a subsidy, carve-out, or commemorative act.
What the text implies
- Most-favored-nation pricing may incentivize pharmaceutical companies to raise prices in other developed countries to offset U.S. losses, shifting cost burden internationally.
- Individual drug importation certification could create supply-chain complexity and potential counterfeit-drug risks if enforcement mechanisms are weak.
The full analysis lists 4 implications of this text.
Who stands to gain
patients and consumers (lower out-of-pocket drug costs); pharmacy benefit managers (potential new direct-to-consumer channel); generic drug manufacturers (increased competitive pressure on branded drugs)